Jump to main content
eTG Complete
Index
Search
Home
Antibiotic
Directed therapy for pneumonia
Pneumocystis jirovecii pneumonia (PJP)
Treatment of high-severity Pneumocystis jirovecii pneumonia (PJP)
Antibiotic
Bartonella infections
Osteomyelitis
Septic arthritis of a native joint
Bone and joint infections other than osteomyelitis and native joint septic arthritis
Sepsis or septic shock associated with a bone or joint source
Directed therapy for native bone or joint infection
Brucellosis
Infective endocarditis
Cardiovascular system infections other than endocarditis
Central nervous system infections
Coronavirus disease 2019 (COVID-19)
Cryptococcosis
Cytomegalovirus (CMV) infection
Infectious diarrhoea
Ear, nose and throat infections
Eye infections
Febrile neutropenia
Genital and sexually transmissible infections
Human immunodeficiency virus
Intra-abdominal infections
Leptospirosis
Lyme disease
Mediastinitis
Melioidosis
Mpox (monkeypox)
Nocardiosis
Nontuberculous mycobacterial infections
Oesophageal infections
Parasitic infections
Perinatal infections
Prevention of infection
Q fever
Pneumonia
Directed therapy for pneumonia
Directed therapy for pneumonia
Acinetobacter baumannii pneumonia in adults
Enterobacterales pneumonia
Haemophilus influenzae pneumonia
Legionella pneumonia in adults
Mycoplasma pneumoniae pneumonia and Chlamydophila (Chlamydia) species pneumonia
Pseudomonas aeruginosa pneumonia
Staphylococcus aureus (staphylococcal) pneumonia
Stenotrophomonas maltophilia pneumonia
Streptococcus pneumoniae (pneumococcal) pneumonia
Overview of fungal pneumonia
Aspergillosis
Pneumocystis jirovecii pneumonia (PJP)
Overview of Pneumocystis jirovecii pneumonia (PJP)
Assessment of Pneumocystis jirovecii pneumonia (PJP) disease severity
Treatment of low- to moderate-severity Pneumocystis jirovecii pneumonia (PJP)
Treatment of high-severity Pneumocystis jirovecii pneumonia (PJP)
Approach to managing high-severity PJP
Preferred antimicrobial therapy for high-severity PJP
Treatment for high-severity PJP in patients with hypersensitivity to trimethoprim+sulfamethoxazole
Corticosteroid therapy for high-severity PJP
Maintenance therapy for Pneumocystis jirovecii pneumonia (PJP)
References
Respiratory tract infections other than pneumonia
Acute rheumatic fever
Rickettsial infections
Salivary gland infections
Sepsis and septic shock: Identification and initial management
Sepsis and septic shock: Empirical regimens
Directed therapy for bloodstream infections, including sepsis and septic shock
Skin and soft tissue infections
Traumatic wound infections
Urinary tract infections in adults
Urinary tract infections in children
Identifying resistant pathogens or Candida species
Principles of obtaining blood for culture
Principles of antimicrobial use
Antimicrobial stewardship (AMS)
Practical information on using antimicrobial drugs
Aminoglycoside use
Vancomycin use in adults
Vancomycin use in young infants and children
Monitoring antimicrobial blood concentrations
Ambulatory antimicrobial therapy
Antimicrobial hypersensitivity
Kidney impairment and antimicrobial dosing
Contact details for health departments and public health units
Amikacin initial dose calculator
Gentamicin initial dose calculator
Tobramycin initial dose calculator
Treatment of high-severity Pneumocystis jirovecii pneumonia (PJP)
Approach to managing high-severity PJP
Preferred antimicrobial therapy for high-severity PJP
Treatment for high-severity PJP in patients with hypersensitivity to trimethoprim+sulfamethoxazole
Corticosteroid therapy for high-severity PJP
